478 related articles for article (PubMed ID: 9773261)
21. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
Siegberg R; Nilsson CG; Stenman UH; Widholm O
Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
[TBL] [Abstract][Full Text] [Related]
22. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of levonorgestrel in 18 women after 1 month of treatment with a triphasic oral contraceptive.
Kuhnz W; al-Yacoub G
Horm Res; 1991; 35(5):178-81. PubMed ID: 1802819
[TBL] [Abstract][Full Text] [Related]
24. Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets.
Abdalla KA; Shabaan MM; Stanczyk FZ
Contraception; 1992 Feb; 45(2):111-8. PubMed ID: 1559334
[TBL] [Abstract][Full Text] [Related]
25. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.
Wiegratz I; Kutschera E; Lee JH; Moore C; Mellinger U; Winkler UH; Kuhl H
Contraception; 2003 Jan; 67(1):25-32. PubMed ID: 12521654
[TBL] [Abstract][Full Text] [Related]
26. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
28. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
[TBL] [Abstract][Full Text] [Related]
29. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
Nielsen CH; Poulsen HK; Teisner B; Thorsen P; Hau J; Westergaard JG
Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):63-71. PubMed ID: 7506680
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
31. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate.
Klove KL; Roy S; Lobo RA
Contraception; 1984 Apr; 29(4):319-24. PubMed ID: 6235099
[TBL] [Abstract][Full Text] [Related]
32. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
Palatsi R; Reinilä M; Kivinén S
Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
[TBL] [Abstract][Full Text] [Related]
33. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
Masson S; Franssen E; Hilditch JR; Powell MG
Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
Scott JZ; Kletzky OA; Brenner PF; Mishell DR
Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
[TBL] [Abstract][Full Text] [Related]
35. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
Carlborg L
Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
[TBL] [Abstract][Full Text] [Related]
36. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
37. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
39. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
